Financial Ratios Sartorius Stedim Biotech
Equities
DIM
FR0013154002
Medical Equipment, Supplies & Distribution
|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 181.60 EUR | +0.44% |
|
+4.85% | -13.52% |
| 30/03 | Goldman Sachs upgrades Sartorius Stedim Biotech to Buy | |
| 30/03 | Goldman Sachs Upgrades Sartorius Stedim Biotech to Buy, Lowers PT | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 16.21 | 15.48 | 4.58 | 3.1 | 4.14 | |||||
Return on Total Capital | 25.04 | 23.22 | 5.86 | 3.74 | 4.94 | |||||
Return On Equity % | 25.94 | 41.43 | 12.03 | 5.33 | 6.53 | |||||
Return on Common Equity | 26.79 | 42.68 | 12.18 | 5.29 | 6.58 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 53.79 | 52.52 | 44.44 | 43.41 | 45.33 | |||||
SG&A Margin | 18.43 | 17.22 | 22.26 | 23.38 | 22.33 | |||||
EBITDA Margin % | 34.43 | 36.04 | 23.7 | 22.64 | 26.22 | |||||
EBITA Margin % | 32.43 | 33.86 | 20.36 | 18.65 | 22.05 | |||||
EBIT Margin % | 30.58 | 31.96 | 16.89 | 14.24 | 18.13 | |||||
Income From Continuing Operations Margin % | 14.35 | 25.19 | 11.24 | 6.42 | 8.96 | |||||
Net Income Margin % | 14.35 | 25.08 | 11.16 | 6.3 | 8.95 | |||||
Net Avail. For Common Margin % | 14.35 | 25.08 | 11.16 | 6.3 | 8.95 | |||||
Normalized Net Income Margin | 19.17 | 18.28 | 7.6 | 5.54 | 8.12 | |||||
Levered Free Cash Flow Margin | 13.92 | 3.8 | 2.93 | 13.3 | 5.97 | |||||
Unlevered Free Cash Flow Margin | 14.14 | 4.12 | 5.53 | 16.63 | 8.88 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.85 | 0.77 | 0.43 | 0.35 | 0.37 | |||||
Fixed Assets Turnover | 4.98 | 4.82 | 3.01 | 2.53 | 2.29 | |||||
Receivables Turnover (Average Receivables) | 9.42 | 9.18 | 7.95 | 9.94 | 12.94 | |||||
Inventory Turnover (Average Inventory) | 2.13 | 1.83 | 1.62 | 2.01 | 2.36 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.4 | 1.61 | 1.51 | 1.85 | 1.02 | |||||
Quick Ratio | 0.59 | 0.53 | 0.49 | 1.05 | 0.47 | |||||
Operating Cash Flow to Current Liabilities | 0.67 | 0.59 | 0.8 | 0.87 | 0.49 | |||||
Days Sales Outstanding (Average Receivables) | 38.74 | 39.74 | 45.92 | 36.84 | 28.21 | |||||
Days Outstanding Inventory (Average Inventory) | 171.56 | 198.96 | 225.72 | 182.3 | 154.78 | |||||
Average Days Payable Outstanding | 47.25 | 48.3 | 66.5 | 75.62 | 65.88 | |||||
Cash Conversion Cycle (Average Days) | 163.05 | 190.4 | 205.14 | 143.52 | 117.1 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 36.09 | 45.17 | 137.73 | 71.31 | 62.99 | |||||
Total Debt / Total Capital | 26.52 | 31.12 | 57.94 | 41.63 | 38.65 | |||||
LT Debt/Equity | 33.76 | 44.22 | 134.77 | 69.71 | 48.92 | |||||
Long-Term Debt / Total Capital | 24.8 | 30.46 | 56.69 | 40.69 | 30.01 | |||||
Total Liabilities / Total Assets | 56.13 | 50.37 | 65.46 | 51.26 | 48.32 | |||||
EBIT / Interest Expense | 86.61 | 61.34 | 4.06 | 2.68 | 3.9 | |||||
EBITDA / Interest Expense | 99 | 70.26 | 5.92 | 4.43 | 5.82 | |||||
(EBITDA - Capex) / Interest Expense | 67.21 | 46.6 | 1.81 | 2.13 | 2.97 | |||||
Total Debt / EBITDA | 0.62 | 0.89 | 5.39 | 4.38 | 3.23 | |||||
Net Debt / EBITDA | 0.39 | 0.79 | 5.21 | 3.33 | 2.69 | |||||
Total Debt / (EBITDA - Capex) | 0.91 | 1.34 | 17.61 | 9.09 | 6.33 | |||||
Net Debt / (EBITDA - Capex) | 0.57 | 1.18 | 17.01 | 6.91 | 5.27 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 51.14 | 20.98 | -20.53 | 0.16 | 6.74 | |||||
Gross Profit, 1 Yr. Growth % | 54.79 | 18.13 | -32.12 | -2.21 | 11.49 | |||||
EBITDA, 1 Yr. Growth % | 72.16 | 22.06 | -45.04 | -4.32 | 23.65 | |||||
EBITA, 1 Yr. Growth % | 75.68 | 21.46 | -49.57 | -8.25 | 26.23 | |||||
EBIT, 1 Yr. Growth % | 75.46 | 21.32 | -55.55 | -15.64 | 35.88 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 22.36 | 112.38 | -64.53 | -42.92 | 48.96 | |||||
Net Income, 1 Yr. Growth % | 23.36 | 111.41 | -64.65 | -43.57 | 51.68 | |||||
Normalized Net Income, 1 Yr. Growth % | 84.78 | 15.32 | -66 | -27.22 | 56.36 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 23.51 | 111.45 | -64.65 | -46.26 | 50.88 | |||||
Accounts Receivable, 1 Yr. Growth % | 38.58 | 13.65 | -27.41 | -9.47 | -27.49 | |||||
Inventory, 1 Yr. Growth % | 66.22 | 30.88 | -13.9 | -22.38 | 0.88 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 23.46 | 26.21 | 28.18 | 12.25 | 23.08 | |||||
Total Assets, 1 Yr. Growth % | 38.31 | 28.2 | 52.8 | 6.81 | -3.3 | |||||
Tangible Book Value, 1 Yr. Growth % | 13.69 | 120.96 | -386.33 | -83.5 | -91.25 | |||||
Common Equity, 1 Yr. Growth % | 15.14 | 47.91 | 7.7 | 51.09 | 2.61 | |||||
Cash From Operations, 1 Yr. Growth % | 66.95 | -12.77 | 21.9 | 9.2 | -15.08 | |||||
Capital Expenditures, 1 Yr. Growth % | 103.52 | 32.9 | 9.99 | -28.25 | 15.72 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 83.34 | -68.79 | -13.32 | 356.26 | -52.08 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 82.86 | -66.62 | 45.81 | 201.81 | -43 | |||||
Dividend Per Share, 1 Yr. Growth % | 85.29 | 14.29 | -52.08 | 0 | 0 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 41.56 | 35.22 | -1.95 | -10.78 | 3.4 | |||||
Gross Profit, 2 Yr. CAGR % | 44.06 | 35.22 | -10.88 | -18.51 | 4.41 | |||||
EBITDA, 2 Yr. CAGR % | 57.33 | 47.67 | -20.14 | -27.49 | 8.77 | |||||
EBITA, 2 Yr. CAGR % | 60.03 | 48.97 | -23.81 | -31.98 | 7.62 | |||||
EBIT, 2 Yr. CAGR % | 59.29 | 48.96 | -28.63 | -38.72 | 7.07 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 32.49 | 61.2 | -13.21 | -54.96 | -7.79 | |||||
Net Income, 2 Yr. CAGR % | 32.94 | 61.49 | -13.55 | -55.29 | -7.48 | |||||
Normalized Net Income, 2 Yr. CAGR % | 63.38 | 45.98 | -38.25 | -50.18 | 6.68 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 33.04 | 61.6 | -13.55 | -56.37 | -9.96 | |||||
Accounts Receivable, 2 Yr. CAGR % | 26.85 | 25.5 | -9.17 | -18.93 | -18.98 | |||||
Inventory, 2 Yr. CAGR % | 54.26 | 47.5 | 6.16 | -18.25 | -11.51 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 16.7 | 24.82 | 27.19 | 19.95 | 17.54 | |||||
Total Assets, 2 Yr. CAGR % | 46.32 | 33.16 | 39.96 | 27.67 | 1.63 | |||||
Tangible Book Value, 2 Yr. CAGR % | -33.55 | 58.5 | 151.53 | -31.44 | -87.99 | |||||
Common Equity, 2 Yr. CAGR % | 19.54 | 30.5 | 26.22 | 27.58 | 24.51 | |||||
Cash From Operations, 2 Yr. CAGR % | 49.8 | 21.19 | 3.12 | 15.38 | -3.7 | |||||
Capital Expenditures, 2 Yr. CAGR % | 54.36 | 64.47 | 20.9 | -11.17 | -8.88 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 64.19 | -22.19 | -56.24 | 98.42 | 47.86 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 64.17 | -19.66 | -40.35 | 109.53 | 31.16 | |||||
Dividend Per Share, 2 Yr. CAGR % | 92.51 | 45.52 | -26 | -30.78 | 0 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 33.55 | 34.34 | 13.27 | -1.25 | -5.29 | |||||
Gross Profit, 3 Yr. CAGR % | 35.12 | 34.84 | 7.13 | -8.07 | -9.54 | |||||
EBITDA, 3 Yr. CAGR % | 42.71 | 46.36 | 4.45 | -15.18 | -13.37 | |||||
EBITA, 3 Yr. CAGR % | 44.37 | 47.89 | 1.98 | -18.95 | -16.41 | |||||
EBIT, 3 Yr. CAGR % | 45.45 | 47.5 | -2.34 | -24.5 | -20.09 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 25.43 | 55.05 | -2.68 | -24.47 | -32.89 | |||||
Net Income, 3 Yr. CAGR % | 25.82 | 55.17 | -2.67 | -24.96 | -32.82 | |||||
Normalized Net Income, 3 Yr. CAGR % | 48.81 | 45.47 | -11.02 | -34.7 | -27.05 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 25.82 | 55.26 | -2.63 | -26.17 | -34.03 | |||||
Accounts Receivable, 3 Yr. CAGR % | 17.36 | 22.29 | 4.56 | -9.27 | -21.89 | |||||
Inventory, 3 Yr. CAGR % | 45.92 | 46.04 | 23.27 | -4.36 | -12.32 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 35.87 | 19.79 | 25.93 | 22 | 20.99 | |||||
Total Assets, 3 Yr. CAGR % | 35.98 | 40.02 | 39.41 | 27.85 | 16.38 | |||||
Tangible Book Value, 3 Yr. CAGR % | -20.48 | -0.81 | 93.04 | 1.27 | -65.49 | |||||
Common Equity, 3 Yr. CAGR % | 16.9 | 28.34 | 22.41 | 34.03 | 18.64 | |||||
Cash From Operations, 3 Yr. CAGR % | 45.21 | 25.45 | 21.43 | 5.11 | 4.17 | |||||
Capital Expenditures, 3 Yr. CAGR % | 22.43 | 46.85 | 43.82 | 1.6 | -2.98 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 139.69 | -3.8 | -28.11 | -4.54 | 23.56 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 135.46 | -1.65 | -11.72 | 2.32 | 35.77 | |||||
Dividend Per Share, 3 Yr. CAGR % | 30.27 | 61.79 | 0.49 | -18.19 | -21.75 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 22.38 | 26.43 | 18.02 | 14.05 | 9.21 | |||||
Gross Profit, 5 Yr. CAGR % | 24.14 | 27.02 | 14.4 | 10.03 | 6.04 | |||||
EBITDA, 5 Yr. CAGR % | 28.79 | 33.55 | 13.98 | 9.4 | 6.15 | |||||
EBITA, 5 Yr. CAGR % | 29.56 | 34.54 | 12.68 | 7.24 | 4.19 | |||||
EBIT, 5 Yr. CAGR % | 29.64 | 34.8 | 10.32 | 2.62 | 1.35 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 21.59 | 39.97 | 8.25 | -5.43 | -4.72 | |||||
Net Income, 5 Yr. CAGR % | 21.95 | 40.31 | 8.28 | -5.67 | -4.59 | |||||
Normalized Net Income, 5 Yr. CAGR % | 31.23 | 33.72 | 4.67 | -5.76 | -4.26 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 21.94 | 40.32 | 8.28 | -6.56 | -5.59 | |||||
Accounts Receivable, 5 Yr. CAGR % | 14.12 | 13.84 | 5.93 | 3.74 | -5.58 | |||||
Inventory, 5 Yr. CAGR % | 35.56 | 40.74 | 28.48 | 15.79 | 7.96 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 23.29 | 28.78 | 32.33 | 19.85 | 22.51 | |||||
Total Assets, 5 Yr. CAGR % | 27 | 29.26 | 37.56 | 34.94 | 22.82 | |||||
Tangible Book Value, 5 Yr. CAGR % | -2.06 | 10.72 | 26.05 | -14.43 | -36.5 | |||||
Common Equity, 5 Yr. CAGR % | 16.92 | 22.94 | 20.54 | 28.03 | 23.25 | |||||
Cash From Operations, 5 Yr. CAGR % | 34.75 | 28.51 | 26.85 | 21.32 | 10.67 | |||||
Capital Expenditures, 5 Yr. CAGR % | 32.37 | 27.69 | 21.82 | 20.1 | 19.82 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 45.73 | 12.28 | 22.78 | 19.93 | -4.16 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 45.08 | 13.42 | 37.48 | 25.01 | 3.38 | |||||
Dividend Per Share, 5 Yr. CAGR % | 24.57 | 25.64 | 3.9 | 15.21 | 0.29 |
- Stock Market
- Equities
- DIM Stock
- Financials Sartorius Stedim Biotech
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















